BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

Dermatitis, pneumonia vaccine data for Pfizer  Pfizer Inc. (NYSE:PFE) reported Phase III data for atopic dermatitis therapy abrocitinib and pneumococcal vaccine 20vPnC Wednesday. The JAK-1 inhibitor met the co-primary efficacy endpoints vs. placebo in the...
BC Extra | Oct 14, 2019
Clinical News

Phase III readout could position Pfizer’s JAK-1 to compete in eczema

Data from the first of two Phase III trials of Pfizer’s JAK-1 inhibitor abrocitinib to treat atopic dermatitis suggest that the oral small molecule could deliver efficacy that ranks with injectable blockbuster Dupixent dupilumab. In...
BC Extra | May 15, 2019
Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
BioCentury | Mar 30, 2018
Emerging Company Profile


MatriSys Bioscience Inc. is developing topical formulations of bacteria derived from the skin microbiome to treat atopic dermatitis and other dermatological conditions, which could be safer than more advanced and marketed therapies that work by...
BC Innovations | Jun 7, 2017
Distillery Therapeutics


INDICATION: Liver cancer Patient sample and mouse studies suggest inhibiting the IL-6 - JAK - STAT3 axis could help treat FGF19 -driven hepatocellular cancer (HCC). In HCC patients, high tumor levels of FGF19 were associated with poor...
BioCentury | Apr 22, 2017
Product Development

Playing JAKs

A desire to improve upon marketed autoimmune drug Xeljanz tofacitinib, coupled with interesting biological findings, led Pfizer Inc. to develop a portfolio of selective Janus kinase inhibitors that are taking the target into new disease...
Items per page:
1 - 6 of 6